Results 151 to 160 of about 29,072 (265)

Sarcopenia Is Associated With Mortality and Progression of Cirrhosis in Decompensated but Not Compensated Disease—A Multicentre Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a retrospective cohort of 1,624 adults with cirrhosis, sarcopenia was independently associated with unplanned hospitalization, death, and cirrhosis progression (or death) in patients with decompensated disease. In compensated cirrhosis, sarcopenia was associated only with a higher risk of unplanned hospitalization.
Puneeta Tandon, Sarah Wang, Moon Young Kim, Bart Van Hoek, Daphne Bot, Jeroen L. A. van Vugt, Berend Beumer, Jan Ijzermans, Sunil Taneja, Ajay Duseja, Surender Singh, Maryam Ebadi, Aldo J. Montano‐Loza   +12 more
wiley   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, EarlyView.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source

Effects of intraduodenally applied bile salts on pancreatic secretion [PDF]

, 1993
Lehnert, Peter, Riepl, Rudolf L.
core   +1 more source

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation

Alimentary Pharmacology &Therapeutics, EarlyView.
Among a nationwide population with primary biliary cholangitis, almost all people were prescribed ursodeoxycholic acid (UDCA). However, UDCA was insufficiently dosed in a one third of them. The results indicate that first‐line treatment can be optimized, particularly in those with a biochemical response and higher body weight.
Ellen Werner, Maria C. B. van Hooff, Gemma H. X. Weijsters, Maria A. van de Vrie, Rozanne C. de Veer, Ulrich Beuers, Joost P. H. Drenth, Frans J. C. Cuperus, Remco van Dijk, Bart J. Veldt, Michael Klemt‐Kropp, Suzanne van Meer, Robert C. Verdonk, Hajo J. Flink, Jan Maarten Vrolijk, Matthijs Kramer, Cyriel Y. Ponsioen, Kirsten Boonstra, Femke Boersma, Hendrik J. M. de Jonge, Frank H. J. Wolfhagen, L. C. Baak, Susanne L. Onderwater, Jeroen D. van Bergeijk, Paul G. van Putten, Gijs J. de Bruin, Rob P. R. Adang, Maria N. Aparicio‐Pages, Wink de Boer, Frank ter Borg, Hanneke van Soest, Elsemieke S. de Vries, Nicole S. Erler, Bettina E. Hansen, Harry L. A. Janssen, Adriaan J. van der Meer, on behalf of the Dutch PBC Study Group, Adriaan J. van der Meer, Anne Vrieze, A. (Sander) van der Beek, Bart J. Veldt, Bart van Hoek, Bettina E. Hansen, Cyriel Y. Ponsioen, Daphne M. Hotho, Djuna L. Cahen, Edith M.M. Kuiper, Ellen Werner, Elsemieke de Vries, Femke Boersma, Frank C. Bekkering, Frank H.J. Wolfhagen, Frank ter Borg, Frans J.C. Cuperus, Gemma X. Weijsters, Gijs J. de Bruin, Hajo J. Flink, Hanneke van Soest, Hans H.K. Thio, Harry L.A. Janssen, Hendrik J.M. de Jonge, Huseyin Aktas, Ingrid C.A.W. Konings, J. Marleen de Vree, J. (Netty) van Kemenade, Jan Maarten Vrolijk, Janne E. van Rooij, Jeroen D. van Bergeijk, Jerome Sint Nicolaas, Johan P.H. Kuyvenhoven, Johannes Schmidt‐Böhmer, Joost P.H. Drenth, Khalida Soufidi, Kirsten Boonstra, Laurens A. van der Waaij, L. (Bert) C. Baak, Leendert H. Oterdoom, Lisette J.H. van Dam, Ludger S.M. Epping, Paul J. Bus, Maaike J. Denters, Marcel Cazemier, Maria C. van Hooff, Maria N. Aparicio‐Pages, Marjo J. Kerbert‐Dreteler, Martijn J. ter Borg, Martine A.M.C. Baven‐Pronk, Matthias C. Jurgens, Matthijs Kramer, Menno Beukema, Merel M. Tielemans, Michael Klemt‐Kropp, Nicole F.M. van Gerven, Nicole S. Erler, Paul G. van Putten, Philip W. Friederich, Pieter C.J. ter Borg, Robert C. Verdonk, Remco van Dijk, Rob P.R. Adang, Robert Roomer, Rozanne C. de Veer, Sander de Kort, Sigrid Vandebosch, Stephan H.C. van Stiphout, Stephan Schmittgens, Sunje Abraham, Susanne L. Onderwater, Suzanne van Meer, Sven J. van den Hazel, Tiki D. Blom, Tim C.M.A. Schreuder, Tom J.G. Gevers, Ulrich Beuers, Ulrike de Wit, Wink de Boer, Yasser A. Alderlieste   +116 more
wiley   +1 more source

Orthotopic liver transplantation [PDF]

, 1995
Gordon, RD, Starzl, TE, Van Thiel, DH
core  

Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D

Alimentary Pharmacology &Therapeutics, EarlyView.
Bulevirtide increases bile acid levels in most patients; however, changes in bile acids do not predict virological response or adverse events, nor do they reflect treatment adherence. After discontinuation of bulevirtide, bile acid levels rapidly decline.
Marlene Hintersteininger, Michael Schwarz, Philipp Schwabl, Lukas Hartl, Lorenz Balcar, Benedikt Silvester Hofer, Georg Kramer, Christian Sebesta, Paul Thöne, Patrik Attalla, Michael Gschwantler, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Mathias Jachs   +14 more
wiley   +1 more source

Targeting Egfr‐Mediated Cell Proliferation and Lipid Metabolism Separation Effectively Accelerate Liver Regeneration

Cell Proliferation, EarlyView.
AREG coordinates cell proliferation and lipid metabolism reprogramming during liver regeneration and targeting lipid metabolism can promote liver regeneration. ABSTRACT Hepatocyte proliferation restores liver mass after partial hepatectomy (PHx), but the metabolic cost of this process remains unclear.
Yuelei Hu, Shifei Song, Ruilin Wang, Ni An, Jinmei Diao, Yuguo Chen, Juan Liu, Guoyue Lv   +7 more
wiley   +1 more source

Which liver-disease patients need a transplant? [PDF]

, 1988
Gordon, RD, Iwatsuki, S, Kahn, D, Klintmalm, G, Koneru, B, Makowka, L, Marsh, JW, Sher, L, Starzl, TE, Staschak, S, Stieber, A, Todo, S, Tzakis, AG, Van Thiel, D   +13 more
core  

Risks and benefits of weaning immunosuppression in liver transplant recipients: Long-term follow-up [PDF]

, 1997
Flynn, B, Fung, JJ, Marino, I, Mazariegos, GV, Reyes, J, Starzl, IE   +5 more
core   +1 more source

Impact of Treatment Response to Anticoagulant Therapy on Liver‐Related Events in Patients With Cirrhosis and Portal Vein Thrombosis

Hepatology Research, EarlyView.
In patients with cirrhosis and a first portal vein thrombosis treated with intravenous anticoagulant therapy, the 3‐year cumulative rates of liver‐related events were 56.7% and 75.5% in the effective and ineffective groups, respectively. A good radiological response was associated with fewer liver‐related hospitalizations.
Atsushi Maeda, Yuki Tahata, Hayato Hikita, Hisashi Ishida, Takayuki Yakushijin, Masanori Nakahara, Kazuyoshi Ohkawa, Fumihiko Nakanishi, Sadaharu Iio, Ryotaro Sakamori, Mitsuru Sakakibara, Masanori Miyazaki, Yuta Myoin, Kazuki Maesaka, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Takahiro Kodama, Tetsuo Takehara   +19 more
wiley   +1 more source